Company goes all out to fully support clients
Gaining GLP/GMP accreditation to provide greater assurance of data integrity for clients looking to take their compounds to IND.
Concept Life Sciences recently announced the completion of the first phase of its GXP compliance plan, achieving GLP (good laboratory practice) accreditation of its Dundee site for in vitro safety studies and bioanalysis. The company is also planning to gain GMP accreditation at the company’s facilities across the UK, to expand services to manufacture of API material. John Handley, Chief Operating Officer at Concept Life Sciences, explains why the company is seeking GLP/GMP certification and what it is doing to ensure success.
Which sites is Concept planning to be GMP/GLP accredited? Why these sites and why now?
Our current plan is to develop our Dundee site to cover all the assays (Bioanalysis, Dermal, In vitro cellular bioassays and Toxicology) under GLP accreditation. In addition, we are working with the Alderley Park team to establish GLP toxicology studies. At Bradford, we will expand our service offerings to include GLP Analytical work to support the chemical and agrochemical sectors, as well as running the GMP-accredited pharma services for batch release, stability and product development. We will then complement our Bradford GMP services by expanding the Sandwich facility to offer cGMP manufacture of API up to 5 kg; this allows the production of sufficient material to run IND studies.
In the past, we have run many of our in vitro, in vivo and analytical studies to the general principles of GLP without making any claim of accreditation, but to be able to fully support clients in taking their compounds to IND the studies must be completed to GLP. Furthermore, the increasing number of chemical and agrochemical clients we serve were seeking much greater assurance of data integrity, hence for all these reasons the right decision is to have our facilities GLP accredited.
What is Concept doing or has done to ensure its relevant sites gain the accreditation?
We have dedicated teams with their own individual Project Manager who runs the program of work needed to gain accreditation at each of our sites. Each team reports to a Steering Committee that reviews weekly progress made against a plan. The teams are made up of operational and quality staff, as well as local site management. The teams monitor the progress of the quality systems implementation (SOPs, policies, audits), training, recruitment of new experienced staff, and any necessary facility upgrades/changes required to gain accreditation.
We are also engaging with external specialist consultants where necessary to advise on specific areas, such as cGMP to complement the knowledge of our existing staff. In addition, we have held discussions with the MHRA about our plans and are updating them regularly.
How will the accreditation expand services to manufacture API material and further support the development of compounds from the discovery stage to full IND packages?
The addition of cGMP manufacture of the API and the GLP services to cover the studies required for IND packages will provide the client with a more complete service offering. Furthermore, the newly formed Program Management department will coordinate, monitor, report and act as the client advocate, ensuring work is completed on time and on budget to provide a high-quality service offering.
Comparing now with post GXP accreditation, how exactly will clients benefit?
The benefits to clients as a result of these additions will not only include added data integrity, but also a more complete service offering to fully support their needs.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance